Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $45.00

Enliven Therapeutics (NASDAQ:ELVN) had its price target raised by equities research analysts at Mizuho from $41.00 to $45.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s price target suggests a potential upside of 26.99% from the stock’s previous close.

A number of other analysts also recently weighed in on ELVN. Wall Street Zen downgraded Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $41.80.

Enliven Therapeutics Stock Up 13.8%

Shares of NASDAQ ELVN traded up $4.29 during mid-day trading on Wednesday, reaching $35.44. 2,852,680 shares of the company were exchanged, compared to its average volume of 1,180,769. Enliven Therapeutics has a 52 week low of $13.30 and a 52 week high of $36.72. The stock has a market capitalization of $2.12 billion, a PE ratio of -19.04 and a beta of 0.33. The company’s 50 day moving average price is $27.85 and its 200 day moving average price is $22.63.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.06). On average, sell-side analysts predict that Enliven Therapeutics will post -1.95 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Richard A. Heyman sold 9,635 shares of Enliven Therapeutics stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $25.03, for a total value of $241,164.05. Following the completion of the transaction, the director owned 25,545 shares of the company’s stock, valued at $639,391.35. The trade was a 27.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joseph P. Lyssikatos sold 91,198 shares of the company’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.22, for a total transaction of $2,482,409.56. Following the completion of the transaction, the insider owned 765,188 shares in the company, valued at approximately $20,828,417.36. The trade was a 10.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 232,180 shares of company stock worth $6,217,033 in the last 90 days. Corporate insiders own 25.90% of the company’s stock.

Institutional Trading of Enliven Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ELVN. Mirae Asset Global Investments Co. Ltd. raised its stake in Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after buying an additional 594 shares during the last quarter. BNP Paribas Financial Markets increased its position in Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in Enliven Therapeutics in the fourth quarter valued at about $83,000. Quantbot Technologies LP boosted its position in Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Enliven Therapeutics during the 4th quarter valued at about $95,000. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.